Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb 4:12:100213.
doi: 10.1016/j.ynstr.2020.100213. eCollection 2020 May.

Allopregnanolone in premenstrual dysphoric disorder (PMDD): Evidence for dysregulated sensitivity to GABA-A receptor modulating neuroactive steroids across the menstrual cycle

Liisa Hantsoo  1 , C Neill Epperson  2
Affiliations

Allopregnanolone in premenstrual dysphoric disorder (PMDD): Evidence for dysregulated sensitivity to GABA-A receptor modulating neuroactive steroids across the menstrual cycle

Liisa Hantsoo et al. Neurobiol Stress. .

Abstract

Premenstrual dysphoric disorder (PMDD) is a severe mood disorder with core symptoms (affective lability, irritability, depressed mood, anxiety) and increased sensitivity to stress occurring in the luteal phase of the menstrual cycle. PMDD can be conceptualized as a disorder of suboptimal sensitivity to neuroactive steroid hormones (NASs). In this review, we describe the role of the NAS allopregnanolone (ALLO), a positive allosteric modulator of the GABAA receptor (GABAA-R), in PMDD's pathophysiology. We review evidence of impaired interaction between ALLO and GABAA-Rs in terms of affective symptom expression, with evidence from rodent and human studies. We discuss evidence of increased luteal phase stress sensitivity as a result of poor ALLO-GABA control of the HPA axis. Finally, we describe how treatments such as selective serotonin reuptake inhibitors (SSRIs) and new drugs targeting GABAA-Rs provide evidence for impaired ALLO-GABA function in PMDD. In sum, the literature supports the hypothesis that PMDD pathophysiology is rooted in impaired GABAA-R response to dynamic ALLO fluctuations across the menstrual cycle, manifesting in affective symptoms and poor regulation of physiologic stress response.

Keywords: Allopregnanolone; Menstrual cycle; Premenstrual dysphoric disorder; Premenstrual syndrome; Progesterone; Women's health.

PubMed Disclaimer

References

    1. Agís-Balboa R.C., Pinna G., Zhubi A., Maloku E., Veldic M., Costa E., Guidotti A. Characterization of brain neurons that express enzymes mediating neurosteroid biosynthesis. Proc. Natl. Acad. Sci. U. S. A. 2006;103:14602–14607. doi: 10.1073/pnas.0606544103. - DOI - PMC - PubMed
    1. Altemus M., Sarvaiya N., Epperson C.N. Sex differences in anxiety and depression clinical perspectives. Front. Neuroendocrinol. 2014;35:320–330. doi: 10.1016/j.yfrne.2014.05.004. - DOI - PMC - PubMed
    1. Alvarez R.P., Chen G., Bodurka J., Kaplan R., Grillon C. Phasic and sustained fear in humans elicits distinct patterns of brain activity. Neuroimage. 2011;55:389–400. doi: 10.1016/j.neuroimage.2010.11.057. - DOI - PMC - PubMed
    1. Bäckström T., Haage D., Löfgren M., Johansson I.M., Strömberg J., Nyberg S., Andréen L., Ossewaarde L., van Wingen G.A., Turkmen S., Bengtsson S.K. Paradoxical effects of GABA-A modulators may explain sex steroid induced negative mood symptoms in some persons. Neuroscience. 2011;191:46–54. doi: 10.1016/j.neuroscience.2011.03.061. - DOI - PubMed
    1. Ball D.M., Glue P., Wilson S., Nutt D.J. Pharmacology of saccadic eye movements in man. 1. Effects of the benzodiazepine receptor ligands midazolam and flumazenil. Psychopharmacology. 1991;105:361–367. doi: 10.1007/bf02244431. - DOI - PubMed